Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases

Dragana Protic, Elber Y. Aydin, Flora Tassone, Maria M. Tan, Randi J Hagerman, Andrea Schneider

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The majority of individuals with fragile X syndrome (FXS) have intellectual disability, behavioral problems, autism, and language deficits. IQ typically declines with age in boys with the full mutation. The results of preclinical studies demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues multiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies of patients with FXS demonstrated improvements in behavior. Methods: Here, we present two cases of individuals who have been treated with metformin clinically for one year. Results: Both patients demonstrated significant cognitive and behavioral improvements. They also improved eating habits and normalization of their weight percentiles. Conclusion: Metformin may be a candidate drug for treatment of several types of symptoms in individuals with FXS.

Original languageEnglish (US)
Article numbere00745
JournalMolecular Genetics and Genomic Medicine
Volume7
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Fragile X Syndrome
Metformin
Biguanides
Feeding Behavior
Autistic Disorder
Intellectual Disability
Type 2 Diabetes Mellitus
Drosophila
Language
Phenotype
Weights and Measures
Mutation
Pharmaceutical Preparations
Therapeutics

Keywords

  • cognition improvement
  • fragile X syndrome
  • metformin
  • targeted treatment

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. / Protic, Dragana; Aydin, Elber Y.; Tassone, Flora; Tan, Maria M.; Hagerman, Randi J; Schneider, Andrea.

In: Molecular Genetics and Genomic Medicine, Vol. 7, No. 7, e00745, 01.07.2019.

Research output: Contribution to journalArticle

@article{cdc1782a819047a5a8ab709f8aef740d,
title = "Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases",
abstract = "Background: The majority of individuals with fragile X syndrome (FXS) have intellectual disability, behavioral problems, autism, and language deficits. IQ typically declines with age in boys with the full mutation. The results of preclinical studies demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues multiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies of patients with FXS demonstrated improvements in behavior. Methods: Here, we present two cases of individuals who have been treated with metformin clinically for one year. Results: Both patients demonstrated significant cognitive and behavioral improvements. They also improved eating habits and normalization of their weight percentiles. Conclusion: Metformin may be a candidate drug for treatment of several types of symptoms in individuals with FXS.",
keywords = "cognition improvement, fragile X syndrome, metformin, targeted treatment",
author = "Dragana Protic and Aydin, {Elber Y.} and Flora Tassone and Tan, {Maria M.} and Hagerman, {Randi J} and Andrea Schneider",
year = "2019",
month = "7",
day = "1",
doi = "10.1002/mgg3.745",
language = "English (US)",
volume = "7",
journal = "Molecular genetics & genomic medicine",
issn = "2324-9269",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases

AU - Protic, Dragana

AU - Aydin, Elber Y.

AU - Tassone, Flora

AU - Tan, Maria M.

AU - Hagerman, Randi J

AU - Schneider, Andrea

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: The majority of individuals with fragile X syndrome (FXS) have intellectual disability, behavioral problems, autism, and language deficits. IQ typically declines with age in boys with the full mutation. The results of preclinical studies demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues multiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies of patients with FXS demonstrated improvements in behavior. Methods: Here, we present two cases of individuals who have been treated with metformin clinically for one year. Results: Both patients demonstrated significant cognitive and behavioral improvements. They also improved eating habits and normalization of their weight percentiles. Conclusion: Metformin may be a candidate drug for treatment of several types of symptoms in individuals with FXS.

AB - Background: The majority of individuals with fragile X syndrome (FXS) have intellectual disability, behavioral problems, autism, and language deficits. IQ typically declines with age in boys with the full mutation. The results of preclinical studies demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues multiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies of patients with FXS demonstrated improvements in behavior. Methods: Here, we present two cases of individuals who have been treated with metformin clinically for one year. Results: Both patients demonstrated significant cognitive and behavioral improvements. They also improved eating habits and normalization of their weight percentiles. Conclusion: Metformin may be a candidate drug for treatment of several types of symptoms in individuals with FXS.

KW - cognition improvement

KW - fragile X syndrome

KW - metformin

KW - targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85068917031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068917031&partnerID=8YFLogxK

U2 - 10.1002/mgg3.745

DO - 10.1002/mgg3.745

M3 - Article

C2 - 31104364

AN - SCOPUS:85068917031

VL - 7

JO - Molecular genetics & genomic medicine

JF - Molecular genetics & genomic medicine

SN - 2324-9269

IS - 7

M1 - e00745

ER -